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Abstract The Spi-B transcription factor is an Ets protein
expressed in B lymphoid cells and closely related to the Spi-1/
PU.1 oncoprotein. By mutational analysis, we showed that Spi-B
is phosphorylated by casein kinase II in vitro on four serine
residues. Mutation of these four serines to alanines prevented the
phosphorylation of Spi-B in vivo, increased the ability of Spi-B to
transactivate expression of a reporter gene and led to a decrease
of Spi-B stability. We propose that the phosphorylation of Spi-B
may participate in the modulation of Spi-B functional activity by
controlling its intracellular protein level.
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1. Introduction
The Spi-B transcription factor [1] is an Ets protein closely
related to the Spi-1/PU.1 oncoprotein [2] and to a lesser extent
to the recently characterized Spi-C [3]. Spi-B and Spi-1/PU.1
are co-expressed in B lymphoid cells and bind in vitro similar
consensus DNA sequences containing a purine-rich central
core 5P-A/GGAA-3P [4]. However, they have not redundant
functions in lymphopoiesis in vivo, as suggested by gene tar-
geting experiments. Mice with a null-mutation in the spi-B
gene develop normally but exhibit a major alteration of the
B cell function [5] whereas the PU.13=3 mice present defects
in the development of neutrophils and T lymphocytes, an
absence of B cells and macrophages and a reduced number
of lymphoid-myeloid precursor cells [6,7]. These data raise the
question of the regulation process leading to the di¡erent bio-
logical activities between Spi-B and Spi-1/PU.1.
Phosphorylation is a post-translational modi¢cation able to
a¡ect the intrinsic activity of a transcription factor by regu-
lating its DNA binding and/or its transcriptional capacity [8].
It can also in£uence subcellular localization, interaction with
some protein partners and proteolysis of the protein. Spi-B is
phosphorylated by the casein kinase II (CKII) in vitro [9]. To
further investigate the consequences of phosphorylation on
Spi-B function, we mapped the phosphorylation sites of Spi-
B in vitro and in vivo. By systematic mutational analysis, we
showed that Spi-B is phosphorylated by CKII on four serine
residues. Mutations of these four serines to alanines prevented
Spi-B phosphorylation in vivo and led to an increase of both
the stability and the transcriptional activity of the protein.
These results indicate that a role of Spi-B phosphorylation
might be to control the intracellular level of Spi-B protein
and by this way to a¡ect its biological activity.
2. Materials and methods
2.1. Plasmid constructs
pGEX vectors were used to express glutathione-S-transferase
(GST)-Spi-B fusion proteins in DH5K bacteria (Fig. 1). GST-Spi-B,
GST-160, GST-108 and GST-DNA binding domain (DBD) were de-
scribed [9]. GST-59, GST-60-108 and GST-PEST were constructed
and a series of GST fusion proteins with mutation of serine residues
to alanine within Spi-B were generated by PCR mutagenesis and
con¢rmed by sequencing.
In eukaryotic cells, pCS3-MT(MycTag) vector, under the control of
the CMV promoter, was used to express Myc-tagged proteins recog-
nized by the 9E10 monoclonal antibody (Santa Cruz Biotechnology)
[10]. pCS3-MT-Spi-B and pCS3-MT-Spi-BvPEST encode wild-type
Spi-B and Spi-B deleted of the PEST domain, respectively. pCS3-
MT-Spi-B(S-37-A), pCS3-MT-Spi-B(S-129,144,146-A) and pCS3-
MT-Spi-B(S-37,129,144,146-A) encode Spi-B proteins with the indi-
cated serine to alanine substitutions.
For luciferase assays, ptk-luc-c-fes plasmid was used as a reporter
[11] in which the expression of the ¢re£y luciferase reporter gene is
under the control of the thymidine kinase minimal promoter and three
copies of an oligonucleotide exhibiting the Spi-1/PU.1 responsive ele-
ment from the c-fes promoter [4]. Expression of the renilla luciferase
from the pRL-CMV vector (Promega) was used to assess transfection
e⁄ciencies.
2.2. Protein analysis
Nuclear extracts were prepared from HeLa cells [12] and Western
blotting was performed as described elsewhere [4].
For immunoprecipitation, nuclear extracts were diluted in phos-
phate bu¡er (10 mM sodium phosphate (pH 7.4), 100 mM NaCl,
1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 50 mM
NaF, 5 mM Na3VO4, 2 mM PMSF and antiproteases), incubated
with the anti-myc (9E10) antibody for 2 h at 4‡C and immunopreci-
pitates were collected on protein A^Sepharose beads.
2.3. In vitro protein kinase assay
10 Wg of GST-fusion proteins bound to glutathione^Sepharose
beads were resuspended in 200 Wl of kinase bu¡er (20 mM HEPES,
pH 7.5, 10 mM MgCl2, 0.2 mM EGTA, 1 mM DTT) containing 50
WM ATP, 5 WCi of Q-[32P]ATP and 0.1 mU of CKII (Boehringer
Mannheim). After incubation for 30 min at 30‡C, the beads were
washed with washing bu¡er (20 mM HEPES, pH 7.5, 100 mM
NaCl, 0.4% Triton X-100). The phosphorylated proteins were eluted
from the beads, resolved on 0.1% SDS^10% PAGE and visualized by
autoradiography. The amounts of GST fusion proteins were moni-
tored by Coomassie Blue staining of the gel (not shown).
2.4. In vivo phosphorylation of Spi-B protein in HeLa cells
HeLa cells were plated at 4U105 cells per 60-mm-diameter dish
1 day before transfection. They were transfected by the calcium phos-
phate co-precipitation procedure with 5 Wg of pCS3-MT-Spi-B or
pCS3-MT-Spi-B(S-37,129,144,146-A) plasmids. 40 h after transfec-
tion, the cells were incubated for 1 h in 1 ml of PO34 Dulbecco’s
modi¢ed Eagle medium containing 10% fetal calf serum. Then,
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0.5 mCi of [32P]orthophosphate were added in the medium and the
incubation was continued during 3 h. Nuclear extracts were prepared
and the wild-type and mutant myc-tagged Spi-B proteins were immu-
noprecipitated with the anti-myc (9E10) antibody. After SDS^PAGE,
the immunocomplexes were analyzed by autoradiography and West-
ern blotting with anti-Spi-B antibodies [4].
2.5. In vitro dephosphorylation and phosphorylation assay
After immunoprecipitation of nuclear extracts from myc-tagged
Spi-B transfected HeLa cells with the anti-Myc (9E10) antibody, the
immunoprecipitates were collected on protein A^Sepharose beads and
resuspended in 50 Wl of dephosphorylation bu¡er (50 mM Tris, pH
7.8, 0.1 mM EDTA, 1 mM DTT). The dephosphorylation was carried
out for 1 h at 37‡C with 50 units of calf intestinal alkaline phospha-
tase (CIP) (Boehringer Mannheim). The immunoprecipitates were
then used as substrates in an in vitro kinase assay and analyzed as
described above.
2.6. Luciferase assay
HeLa cells were co-transfected with 2.5 Wg of a pCS3-MT (Myc-
Tag) Spi-B expression vector, 0.5 Wg of the ptk-luc-c-fes plasmid and
0.5 Wg of the renilla luciferase control vector (pRL-CMV). The cells
were harvested 48 h after transfection and the luciferase activities were
determined by using a Dual-Luciferase Reporter Assay system (Prom-
ega). The transfection experiments were repeated three times and two
plasmid DNA preparations were used for each Spi-B expression vec-
tor.
2.7. Spi-B degradation analysis
2.5U106 HeLa cells were transfected with 30 Wg of each pCS3-MT
expression vector encoding the various Myc-tagged Spi-B proteins.
16 h after transfection, the cells were harvested by trypsinization
and equal number of cells were replated into ¢ve 60-mm-diameter
dishes. The cultures were treated 24 h after replating either with cyclo-
heximide (Sigma) at 50 Wg/ml or with cycloheximide and ALLN
(N-acetyl-Leu-Leu-norleucinal) (Sigma) at 0.1 mM or with cyclohex-
imide and clasto-lactacystin L-lactone (Calbiochem) at 10 WM. At the
indicated times, nuclear extracts were prepared and analyzed by West-
ern blotting.
3. Results
3.1. Serine residues 37 in the transactivation domain and 129,
144 and 146 in the PEST domain of Spi-B are
phosphorylated by CKII in vitro
To identify the regions and the amino acids targeted by
CKII within Spi-B, various truncated GST fusion proteins
(Fig. 1) were used as substrates for in vitro kinase assays
with puri¢ed CKII in the presence of Q-[32P]ATP. The results
in Fig. 2A showed that GST-Spi-B, GST-160, GST-108, GST-
59 and GST-PEST were phosphorylated. No phosphorylation
was detected in GST-60-108 and GST-DBD. Thus, phosphor-
ylation sites for CKII appeared located in the NH2-terminal
part of the transactivation domain (amino acids positions
from 1 to 59) and in the PEST domain (amino acids positions
from 108 to 160) of the Spi-B protein.
Our previous data showed that GST-108 was mainly phos-
phorylated on serine residues [9]. The phosphorylated NH2-
terminal part, spanning amino acids from 1 to 59, contains
two serines 33 and 43 that lie within a consensus CKII phos-
phorylation site (S*/T*-X-X-E/D). However, GST-108(S-
33,43-A), in which both serines 33 and 43 were mutated to
alanines, appeared phosphorylated as e⁄ciently as the wild-
type GST-108 suggesting that serines 33 and 43 were not
substrate for CKII (Fig. 2B). In contrast, the mutated pro-
teins GST-108(S-32,37-A), GST-108(S-33,37-A) and GST-
108(S-37,43-A) appeared not phosphorylated whereas GST-
108(S-32,33-A) and GST-108(S-32,43-A) were phosphorylated
(Fig. 2B). These experiments showed that the absence of phos-
phorylation is correlated to the substitution of the serine 37 to
alanine, suggesting that the serine 37 might be the CKII phos-
phorylation site in the in vitro kinase assay. As expected,
CKII failed to phosphorylate GST-108(S-37-A) in contrast
with GST-108(S-32,33,43-A) (Fig. 2B). These results demon-
strated that the non-CKII consensus serine 37 is the CKII
phosphorylation site within the NH2-terminal part of the
transactivation domain of Spi-B protein.
The PEST domain contains three serine residues 129, 144
and 146 that belong to a consensus CKII phosphorylation
site. No phosphorylation was observed in the mutant GST-
PEST(S-129,144,146-A) whereas GST-PEST(S-129,144-A),
GST-PEST(S-129,146-A) and GST-PEST(S-144,146-A) were
phosphorylated by CKII (Fig. 2C). These data allowed to
conclude that these three serines are CKII phosphorylation
sites in vitro.
Finally, the full length GST Spi-B with mutations (S-
37,129,144,146-A) appeared not phosphorylated (Fig. 2A).
Fig. 1. Schematic representation of Spi-B and GST fusion proteins.
The open box contains the transactivation domain (TD), the gray
box represents the PEST sequence and the black box contains the
DNA binding domain (DBD) or Ets domain. The serine to alanine
substitutions are shown by a lozenge.
Fig. 2. CKII phosphorylates Spi-B within both the transactivation
domain at serine 37 and the PEST motif at serines 129, 144 and
146 in vitro. GST fusion proteins were used as substrates for in vi-
tro kinase assays with puri¢ed CKII in the presence of Q-[32P]ATP.
The labeled proteins were visualized by autoradiography after SDS^
PAGE.
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This result con¢rmed that the serine residues 37, 129, 144 and
146 are the in vitro CKII phosphorylation sites in Spi-B pro-
tein.
3.2. The CKII phosphorylation sites mapped in vitro are
phosphorylated in vivo
To determine whether the CKII target serines identi¢ed in
vitro were also phosphorylated in vivo, we performed meta-
bolic 32P-labeling of HeLa cells transfected with plasmids ex-
pressing either wild-type or mutated (S-37,129,144,146-A) Spi-
B. As compared to the immunoblotting with anti-Spi-B anti-
bodies showing protein expression, only wild-type Spi-B ap-
peared phosphorylated (Fig. 3A). Moreover, we compared the
ability of CKII to phosphorylate untreated and phosphatase-
treated Spi-B from transfected HeLa cells. In Fig. 3B, the
phosphorylation of Spi-B by CKII was observed only after
phosphatase treatment. Although we cannot determine
whether each of the four serines is a phosphoacceptor site in
vivo, these data strongly suggested that at least one of the
identi¢ed CKII sites was phosphorylated in vivo.
3.3. Mutations of the CKII phosphorylation sites increase the
ability of Spi-B to transactivate
To investigate whether CKII phosphorylation may be in-
volved in Spi-B function, we studied the capacity of Spi-B
mutants to transactivate expression of a luciferase reporter
gene in HeLa transfected cells. As compared to wild-type
Spi-B, we observed an increase in reporter transactivation
with both the mutants Spi-B(S-37,129,144,146-A) and Spi-
B(S-129,144,146-A) whereas no change in transactivation e⁄-
ciency was detected for Spi-B(S-37-A) and Spi-BvPEST (Fig.
4). These results suggested that prevention of CKII phosphor-
ylation in the PEST domain led to the increased ability of Spi-
B to transactivate a reporter gene.
3.4. Spi-B phosphorylation by CKII reduces its stability
Three of the four serines phosphorylated by CKII are lo-
cated within the PEST sequence of Spi-B. PEST sequences are
proposed to serve as signals for proteolytic degradation and
have been frequently reported to contain consensus site(s) for
phosphorylation by CKII, suggesting that CKII phosphoryla-
tion might be a regulation mechanism of PEST-mediated pro-
tein degradation [13]. In order to determine whether the PEST
motif plays a role in the intrinsic stability of Spi-B, we exam-
ined the half-life of wild-type and vPEST Spi-B in HeLa co-
transfected cells after cycloheximide treatment. In Fig. 5A
Spi-B and Spi-BvPEST appeared to be degraded similarly
revealing that deletion of the PEST sequence did not change
Spi-B stability. The half-lives of both the wild-type Spi-B and
Spi-BvPEST proteins were estimated to be 60 min. We further
investigated by the same experimental approach whether the
phosphoserines 37, 129, 144 and 146 might be involved in Spi-
B stability. No alteration of protein stability was observed for
Spi-B(S-37-A) as compared to SpiBvPEST (Fig. 5C). In con-
trast, Spi-B(S-37,129,144,146-A) was found more stable than
Fig. 3. In vivo phosphorylation of Spi-B. A: HeLa cells, transiently
transfected with vectors expressing either wild-type or (S-
37,129,144,146-A) Spi-B, were metabolically labeled with
[32P]orthophosphate. The transfected proteins were immunoprecipi-
tated from nuclear extracts and visualized by autoradiography and
immunoblotting with anti-Spi-B antibodies. B: Spi-B was expressed
in HeLa cells and immunoprecipitated from nuclear extracts. The
immunocomplexes were incubated with or without CIP, then used
as substrates in an in vitro kinase assay with or without CKII in
the presence of Q-[32P]ATP. The resolved proteins were visualized by
autoradiography and Western blotting with anti-Spi-B antibodies.
Fig. 4. Increased transactivating abilities of both the mutants Spi-
B(S-37,129,144,146-A) and Spi-B(S-129,144,146-A). HeLa cells were
co-transfected with a vector expressing the indicated Spi-B protein
and the ¢re£y luciferase reporter vector (ptk-luc-c-fes). Cells were
harvested 48 h post-transfection and luciferase activities were deter-
mined. The data are presented as percentages of the transactivation
ability of wild-type Spi-B, which was set to 100%. The results
shown are means þ S.D. of three separate experiments.
Fig. 5. Increased stabilities of both the mutants Spi-B(S-
37,129,144,146-A) and Spi-B (S-129,144,146-A). HeLa cells, transi-
ently co-transfected with vectors expressing vPEST and either (A)
wild-type or (B) (S-37,129,144,146-A) or (C) (S-37-A) or (D) (S-
129,144,146-A) Spi-B proteins, were treated with cycloheximide for
the indicated times. The transfected proteins were detected in nu-
clear extracts by Western blotting analysis with the anti-Myc anti-
body. Identical blots were subjected to Western analysis with an
anti-actin (I-19) antibody (Santa Cruz Biotechnology) to control
sample loading.
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SpiBvPEST, its half-life being estimated to be increased to
120 min (Fig. 5B). The stability of Spi-B(S-129,144,146-A)
appeared also increased as compared to SpiBvPEST but in-
termediate between those of wild-type and mutated (S-
37,129,144,146-A) Spi-B proteins (Fig. 5D). These results sug-
gested that Spi-B phosphorylation could be involved in the
control of the Spi-B intracellular proteolysis.
3.5. Spi-B degradation is reduced in the presence of a cysteine
protease inhibitor
PEST sequences are most frequently proposed to target
proteins for degradation by the 26S proteasome [13]. We
tested whether the proteasome may be involved in the degra-
dation of Spi-B in vivo by using two proteasome inhibitors:
(1) the clasto-lactacystin L-lactone which is a speci¢c inhibitor
of the 26S proteasome (2) the ALLN (N-acetyl-Leu-Leu-nor-
leucinal) which inhibits both the 26S proteasome and cysteine
proteases including calpains. HeLa cells were transfected with
the Spi-B expression vector and then incubated with cyclo-
heximide in the presence of either ALLN or clasto-lactacystin
L-lactone. ALLN treatment induced an increase in the stabil-
ity of Spi-B whereas treatment with the clasto-lactacystin L-
lactone inhibitor did not (Fig. 6). These data suggested that
the degradation of Spi-B does not proceed by the proteasome
pathway but more probably involves a cysteine protease.
4. Discussion
To investigate the potential role of CKII phosphorylation
on Spi-B activity, we ¢rst identi¢ed serine residues that are
phosphorylated by CKII and then examined their role in Spi-
B transcriptional activity. We showed that the serine residue
37 in the NH2-terminal transactivation domain and the serine
residues 129, 144 and 146 in the PEST domain of Spi-B are
phosphorylated by CKII in vitro. These phosphoserines are
located at positions very similar to those characterized in the
highly related Spi-1/PU.1 oncoprotein [14]. We also showed
that the mutation of the four serines to alanines dramatically
reduced Spi-B phosphorylation in vivo and increase the trans-
activation capacity of Spi-B. CKII phosphorylation has been
already reported to modulate the transcriptional activity of
Spi-1/PU.1. In particular, the physical association between
Spi-1/PU.1 and Pip in B lymphoid cells depends on the phos-
phorylation of the serine 148 within the Spi-1/PU.1 PEST
sequence and increases the transcriptional activity of Spi-1/
PU.1 [15]. Similar transcriptional synergy, depending of the
phosphorylation of S144 was also recently reported for Spi-B
[16].
Spi-B containing three serines phosphorylated by CKII in
its PEST domain, it could be presumed that such phosphor-
ylation might be needed for degradation of Spi-B. Although
deletion of the PEST region does not a¡ect protein turnover
(Fig. 5A), mutation of the three CKII sites in the PEST
domain was found to slightly increase its stability. However,
a greater increase in Spi-B stability was observed when all of
the four serines were mutated to alanines. This suggests that
the CKII phosphorylation of Spi-B within both the NH2-
terminal and PEST domains is implicated in the constitutive
turnover of the protein. The reduced degradation of Spi-B in
the presence of the ALLN proteasome inhibitor suggests that
Spi-B might be degraded by a cysteine protease. Such a role of
CKII phosphorylation in Spi-1/PU.1 stability has not been
reported
The biological activities of numerous cellular proteins have
been reported to be regulated by the modulation of their
protein level through a degradation mechanism [17^19]. The
increased stabilities of the above Spi-B mutants are likely to
be responsible for their increased transactivation capacities
(Fig. 4). However, although Spi-B(S-37,129,144,146-A) exhib-
ited a longer half-life than Spi-B(S-129,144,146-A), they both
showed similar transactivating abilities. Thus, the increased
transcriptional activity of Spi-B(S-129,144,146-A) is probably
not the only consequence of protein stabilization. The lack of
CKII phosphorylation in the PEST domain might also induce
a conformational change and/or a modi¢cation of protein-
protein interaction that modulate Spi-B transcriptional activ-
ity.
In conclusion, our data argue for a role of CKII phosphor-
ylation in the transcriptional activity of Spi-B by controlling
the intracellular level of Spi-B protein through a regulation of
its degradation.
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